Display options
Cite
Hirao H, Ito T, Kadono K, et al. Donor Hepatic Occult Collagen Deposition Predisposes to Peritransplant Stress and Impacts Human Liver Transplantation. Hepatology. 2021;74(5):2759-2773doi: 10.1002/hep.32030.
Hirao, H., Ito, T., Kadono, K., Kojima, H., Naini, B. V., Nakamura, K., Kageyama, S., Busuttil, R. W., Kupiec-Weglinski, J. W., & Kaldas, F. M. (2021). Donor Hepatic Occult Collagen Deposition Predisposes to Peritransplant Stress and Impacts Human Liver Transplantation. Hepatology (Baltimore, Md.), 74(5), 2759-2773. https://doi.org/10.1002/hep.32030
Hirao, Hirofumi, et al. "Donor Hepatic Occult Collagen Deposition Predisposes to Peritransplant Stress and Impacts Human Liver Transplantation." Hepatology (Baltimore, Md.) vol. 74,5 (2021): 2759-2773. doi: https://doi.org/10.1002/hep.32030
Hirao H, Ito T, Kadono K, Kojima H, Naini BV, Nakamura K, Kageyama S, Busuttil RW, Kupiec-Weglinski JW, Kaldas FM. Donor Hepatic Occult Collagen Deposition Predisposes to Peritransplant Stress and Impacts Human Liver Transplantation. Hepatology. 2021 Nov;74(5):2759-2773. doi: 10.1002/hep.32030. Epub 2021 Aug 30. PMID: 34170562.
Copy Download .nbib Format: NLM
Share it on

Hepatology. 2021 Nov;74(5):2759-2773. doi: 10.1002/hep.32030. Epub 2021 Aug 30.

Donor Hepatic Occult Collagen Deposition Predisposes to Peritransplant Stress and Impacts Human Liver Transplantation.

Hepatology (Baltimore, Md.)

Hirofumi Hirao, Takahiro Ito, Kentaro Kadono, Hidenobu Kojima, Bita V Naini, Kojiro Nakamura, Shoichi Kageyama, Ronald W Busuttil, Jerzy W Kupiec-Weglinski, Fady M Kaldas

Affiliations

  1. The Dumont-UCLA Transplantation Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California, Los Angeles, CA.
  2. Department of Pathology, David Geffen School of Medicine at University of California, Los Angeles, CA.
  3. Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Kyoto University, Kyoto, Japan.

PMID: 34170562 DOI: 10.1002/hep.32030

Abstract

BACKGROUND AND AIMS: Environmentally triggered chronic liver inflammation can cause collagen deposits, whereas early stages of fibrosis without any specific symptoms could hardly be detectable. We hypothesized that some of the human donor grafts in clinical liver transplantation (LT) might possess unrecognizable fibrosis, affecting their susceptibility to LT-induced stress and hepatocellular damage. This retrospective study aimed to assess the impact of occult hepatic fibrosis on clinical LT outcomes.

APPROACH AND RESULTS: Human (194) donor liver biopsies were stained for collagen with Sirius red, and positive areas (Sirius red-positive area; SRA) were measured. The body mass index, aspartate aminotransferase/alanine aminotransferase ratio, diabetes score was calculated using 962 cases of the donor data at the procurement. LT outcomes, including ischemia-reperfusion injury (IRI), early allograft dysfunction (EAD), and survival rates, were analyzed according to SRA and BARD scores. With the median SRA in 194 grafts of 9.4%, grafts were classified into low-SRA (<15%; n = 140) and high-SRA (≥15%; n = 54) groups. Grafts with high SRA suffered from higher rates of IRI and EAD (P < 0.05) as compared to those with low SRA. Interestingly, high SRA was identified as an independent risk factor for EAD and positively correlated with the donor BARD score. When comparing low-BARD (n = 692) with high-BARD (n = 270) grafts in the same period, those with high BARD showed significantly higher post-LT transaminase levels and higher rates of IRI and EAD.

CONCLUSIONS: These findings from the largest clinical study cohort to date document the essential role of occult collagen deposition in donor livers on LT outcomes. High-SRA and donor BARD scores correlated with an increased incidence of hepatic IRI and EAD in LT recipients. This study provides the rationale for in-depth and prospective assessment of occult fibrosis for refined personalized LT management.

© 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

References

  1. Hudcova J, Scopa C, Rashid J, Waqas A, Ruthazer R, Schumann R. Effect of early allograft dysfunction on outcomes following liver transplantation. Clin Transplant 2017;31:e12887. - PubMed
  2. Kim WR, Lake JR, Smith JM, Skeans MA, Schladt DP, Edwards EB, et al. Liver. Am J Transplant 2016;16(Suppl. 2):69-98. - PubMed
  3. Agopian VG, Petrowsky H, Kaldas FM, Zarrinpar A, Farmer DG, Yersiz H, et al. The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center. Ann Surg 2013;258:409-421. - PubMed
  4. Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl 2010;16:943-949. - PubMed
  5. Wadei HM, Lee DD, Croome KP, Mai ML, Golan E, Brotman R, et al. Early allograft dysfunction after liver transplantation is associated with short- and long-term kidney function impairment. Am J Transplant 2016;16:850-859. - PubMed
  6. Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 2017;65:804-812. - PubMed
  7. Su F, Yu L, Berry K, Liou IW, Landis CS, Rayhill SC, et al. Aging of liver transplant registrants and recipients: trends and impact on waitlist outcomes, post-transplantation outcomes, and transplant-related survival benefit. Gastroenterology 2016;150:441-453.e6; quiz, e16. - PubMed
  8. Koyama Y, Brenner DA. Liver inflammation and fibrosis. J Clin Invest 2017;127:55-64. - PubMed
  9. Melin C, Miick R, Young NA, Ortiz J, Balasubramanian M. Approach to intraoperative consultation for donor liver biopsies. Arch Pathol Lab Med 2013;137:270-274. - PubMed
  10. Kelly D, Verkade HJ, Rajanayagam J, McKiernan P, Mazariegos G, Hübscher S. Late graft hepatitis and fibrosis in pediatric liver allograft recipients: current concepts and future developments. Liver Transpl 2016;22:1593-1602. - PubMed
  11. Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 2000;6:44-53. - PubMed
  12. Chopra KB, Demetris AJ, Blakolmer K, Dvorchik I, Laskus T, Wang LF, et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 2003;76:1487-1491. - PubMed
  13. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-684. - PubMed
  14. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699. - PubMed
  15. Wadhera V, Harimoto N, Lubezky N, Gomatos I, Facciuto M, Gonzalez D, et al. The impact of donor liver allograft fibrosis on patients undergoing liver transplantation. Clin Transplant 2018;32:e13187. - PubMed
  16. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20(1 Pt. 1):15-20. - PubMed
  17. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998;93:44-48. - PubMed
  18. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526. - PubMed
  19. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-1325. - PubMed
  20. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-854. - PubMed
  21. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-1447. - PubMed
  22. Sosa RA, Zarrinpar A, Rossetti M, Lassman CR, Naini BV, Datta N, et al. Early cytokine signatures of ischemia/reperfusion injury in human orthotopic liver transplantation. JCI Insight 2016;1:e89679. - PubMed
  23. Ito T, Naini BV, Markovic D, Aziz A, Younan S, Lu M, et al. Ischemia-reperfusion injury and its relationship with early allograft dysfunction in liver transplant patients. Am J Transplant 2021;21:614-625. - PubMed
  24. Nakamura K, Kageyama S, Ito T, Hirao H, Kadono K, Aziz A, et al. Antibiotic pretreatment alleviates liver transplant damage in mice and humans. J Clin Invest 2019;129:3420-3434. - PubMed
  25. Nakamura K, Zhang M, Kageyama S, Ke B, Fujii T, Sosa RA, et al. Macrophage heme oxygenase-1-SIRT1-p53 axis regulates sterile inflammation in liver ischemia-reperfusion injury. J Hepatol 2017;67:1232-1242. - PubMed
  26. Nakamura K, Kageyama S, Kaldas FM, Hirao H, Ito T, Kadono K, et al. Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury. J Clin Invest 2020;130:2689-2704. - PubMed
  27. Allaire M, Rautou PE, Codogno P, Lotersztajn S. Autophagy in liver diseases: time for translation? J Hepatol 2019;70:985-998. - PubMed
  28. Croome KP, Lee DD, Burns JM, Keaveny AP, Taner CB. Intraregional model for end-stage liver disease score variation in liver transplantation: disparity in our own backyard. Liver Transpl 2018;24:488-496. - PubMed
  29. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6:783-790. - PubMed
  30. Zhai Y, Petrowsky H, Hong JC, Busuttil RW, Kupiec-Weglinski JW. Ischaemia-reperfusion injury in liver transplantation-from bench to bedside. Nat Rev Gastroenterol Hepatol 2013;10:79-89. - PubMed
  31. Ali JM, Davies SE, Brais RJ, Randle LV, Klinck JR, Allison MED, et al. Analysis of ischemia/reperfusion injury in time-zero biopsies predicts liver allograft outcomes. Liver Transpl 2015;21:487-499. - PubMed
  32. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-251. - PubMed
  33. Sosa RA, Terry AQ, Kaldas FM, Jin YP, Rossetti M, Ito T, et al. Disulfide-HMGB1 drives ischemia-reperfusion injury in human liver transplantation. Hepatology 2021;73:1158-1175. - PubMed
  34. Barbosa MC, Grosso RA, Fader CM. Hallmarks of aging: an autophagic perspective. Front Endocrinol (Lausanne) 2018;9:790. - PubMed
  35. Li J, Lin W, Zhuang L. CD5L-induced activation of autophagy is associated with hepatoprotection in ischemic reperfusion injury via the CD36/ATG7 axis. Exp Ther Med 2020;19:2588-2596. - PubMed
  36. Han YF, Zhao YB, Li J, Li L, Li YG, Li SP, et al. Stat3-Atg5 signal axis inducing autophagy to alleviate hepatic ischemia-reperfusion injury. J Cell Biochem 2018;119:3440-3450. - PubMed
  37. Pyo JO, Yoo SM, Ahn HH, Nah J, Hong SH, Kam TI, et al. Overexpression of Atg5 in mice activates autophagy and extends lifespan. Nat Commun 2013;4:2300. - PubMed
  38. Konishi T, Schuster RM, Goetzman HS, Caldwell CC, Lentsch AB. Fibrotic liver has prompt recovery after ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2020;318:G390-G400. - PubMed
  39. Zhao H, Alam A, Soo AP, George AJT, Ma D. Ischemia-reperfusion injury reduces long term renal graft survival: mechanism and beyond. EBioMedicine 2018;28:31-42. - PubMed
  40. Huang YI, de Boer WB, Adams LA, MacQuillan G, Rossi E, Rigby P, et al. Image analysis of liver collagen using sirius red is more accurate and correlates better with serum fibrosis markers than trichrome. Liver Int 2013;33:1249-1256. - PubMed
  41. Cabibi D, Bronte F, Porcasi R, Ingrao S, Giannone AG, Maida M, et al. Comparison of histochemical stainings in evaluation of liver fibrosis and correlation with transient elastography in chronic hepatitis. Anal Cell Pathol (Amst) 2015;2015:431750. - PubMed
  42. Kumar A, Yamauchi J, Girgenrath T, Girgenrath M. Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A. Hum Mol Genet 2011;20:2333-2343. - PubMed

Publication Types

Grant support